A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis.
A specific, accurate and precise high-performance liquid chromatographic assay was developed for the determination of riluzole, a drug used to treat patients with amyotrophic lateral sclerosis. Samples were treated by extraction with dichloromethane followed by reversed-phase chromatography with ultraviolet detection at 260 nm. Preset validation criteria were met from 20 to 2000 ng/mL with a linear response curve. Extraction recovery of riluzole was 65-76%. The accuracy of the method was 102-103%. Intra- and inter-day coefficients of variation were in the ranges 2.8-4.9% and 1.8-9.7%. A detection limit of 5 ng/mL was found. Determination of concentrations in serum and plasma resulted in similar results below 500 ng/mL. At higher values a matrix effect cannot be excluded. This presented method can be used to monitor plasma or serum levels in ALS patients treated with riluzole.
van Kan
H J M
HJ
Academic Medical Centre, Department of Clinical Pharmacy, Meibergdreef 9, PO Box 22660, 1100 DD Amsterdam, The Netherlands. h.j.vankan@amc.uva.nl
Spieksma
M
M
Groeneveld
G J
GJ
Toraño
J Sastre
JS
van den Berg
L H
LH
Guchelaar
H J
HJ
D000690:Amyotrophic Lateral Sclerosis / Q000097:blood*; D002138:Calibration; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D016903:Drug Monitoring; D018691:Excitatory Amino Acid Antagonists / Q000097:blood*; D012015:Reference Standards; D015203:Reproducibility of Results; D019782:Riluzole / Q000097:blood*; D012680:Sensitivity and Specificity; D013056:Spectrophotometry, Ultraviolet
D018691:Excitatory Amino Acid Antagonists; D019782:Riluzole